Targeting the JNK Signaling Pathway for Stroke and Parkinsons Diseases Therapy
The DOI matches its Crossref record.
Abstract
The c-Jun NH2-terminal Kinase (JNK) signaling pathway is frequently induced by cellular stress and correlated with neuronal death. This unique property makes JNK signaling a promising target for developing pharmacological intervention. Among several neurological disorders, JNK signaling is particularly implicated in ischemic stroke and Parkinson's disease. The inhibitors of the JNK signaling pathway include upstream kinase inhibitors (for example, CEP-1347), small chemical inhibitors of JNK (SP600125 and AS601245), and peptide inhibitors of the interaction between JNK and its substrates (D-JNKI and I-JIP). The mechanisms by which JNK signaling induces apoptosis and evidence of cytoprotective effects of these JNK inhibitors are summarized in the present review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease
Johnson, G. L., & Nakamura, K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.12.009 · Cited by 500
JNK signalling in cancer: in need of new, smarter therapeutic targets
Bubici, C., & Papa, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12432 · Cited by 346
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
The Parkinson Study Group PRECEPT Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000277648.63931.c0 · Cited by 292
Arai, K., Jin, G., Navaratna, D., & Lo, E. H. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07176.x · Cited by 288
Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8295-4 · Cited by 156
“The c-Jun N-terminal kinase (JNK) pathway constitutes a central stress activated response implicated in the pathogenesis of PD [9].”
BackgroundNeuroprotection by histone deacetylase-related protein
Morrison, B. E., Majdzadeh, N., Zhang, X., Lyles, A., Bassel-Duby, R., Olson, E. N., & D'Mello, S. R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3550-3564.2006 · Cited by 100
“Phosphorylation by c-Jun is mediated by JNK, and the requirement for JNK in neuronal apoptosis is well documented (6, 23, 43).”
BackgroundYeste-Velasco, M., Folch, J., Casadesús, G., Smith, M. A., Pallàs, M., & Camins, A. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.035 · Cited by 31
Metadata
- Authors
- Kuan, C.-Y., & Burke, R.
- Venue
- Current Drug Target -CNS & Neurological Disorders
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-02-01
- Volume
- 4
- Issue
- 1
- Pages
- 63-67
- ISSN
- 1568-007X (ISSN-L)
- OpenAlex
- W2021405916
- Cited by
- 100
- References
- 0
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.